Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer
Anil K D'Cruz, Richa Vaish, Neeti Kapre, Mitali Dandekar, Sudeep Gupta, Rohini Hawaldar, Jai Prakash Agarwal, Gouri Pantvaidya, Devendra Chaukar, Anuja Deshmukh, Shubhada Kane, Supreeta Arya, Sarbani Ghosh-Laskar, Pankaj Chaturvedi, Prathamesh Pai, Sudhir Nair, Deepa Nair, Rajendra Badwe, Head and Neck Disease Management Group, Anil K D'Cruz, Jai Prakash Agarwal, Gouri Pantvaidya, Devendra Chaukar, Anuja Deshmukh, Shubhada Kane, Supreeta Arya, Sarbani Ghosh-Laskar, Pankaj Chaturvedi, Prathamesh Pai, Sudhir Nair, Deepa Nair, Anil K D'Cruz, Richa Vaish, Neeti Kapre, Mitali Dandekar, Sudeep Gupta, Rohini Hawaldar, Jai Prakash Agarwal, Gouri Pantvaidya, Devendra Chaukar, Anuja Deshmukh, Shubhada Kane, Supreeta Arya, Sarbani Ghosh-Laskar, Pankaj Chaturvedi, Prathamesh Pai, Sudhir Nair, Deepa Nair, Rajendra Badwe, Head and Neck Disease Management Group, Anil K D'Cruz, Jai Prakash Agarwal, Gouri Pantvaidya, Devendra Chaukar, Anuja Deshmukh, Shubhada Kane, Supreeta Arya, Sarbani Ghosh-Laskar, Pankaj Chaturvedi, Prathamesh Pai, Sudhir Nair, Deepa Nair
Abstract
Background: Whether patients with early-stage oral cancers should be treated with elective neck dissection at the time of the primary surgery or with therapeutic neck dissection after nodal relapse has been a matter of debate.
Methods: In this prospective, randomized, controlled trial, we evaluated the effect on survival of elective node dissection (ipsilateral neck dissection at the time of the primary surgery) versus therapeutic node dissection (watchful waiting followed by neck dissection for nodal relapse) in patients with lateralized stage T1 or T2 oral squamous-cell carcinomas. Primary and secondary end points were overall survival and disease-free survival, respectively.
Results: Between 2004 and 2014, a total of 596 patients were enrolled. As prespecified by the data and safety monitoring committee, this report summarizes results for the first 500 patients (245 in the elective-surgery group and 255 in the therapeutic-surgery group), with a median follow-up of 39 months. There were 81 recurrences and 50 deaths in the elective-surgery group and 146 recurrences and 79 deaths in the therapeutic-surgery group. At 3 years, elective node dissection resulted in an improved rate of overall survival (80.0%; 95% confidence interval [CI], 74.1 to 85.8), as compared with therapeutic dissection (67.5%; 95% CI, 61.0 to 73.9), for a hazard ratio for death of 0.64 in the elective-surgery group (95% CI, 0.45 to 0.92; P=0.01 by the log-rank test). At that time, patients in the elective-surgery group also had a higher rate of disease-free survival than those in the therapeutic-surgery group (69.5% vs. 45.9%, P<0.001). Elective node dissection was superior in most subgroups without significant interactions. Rates of adverse events were 6.6% and 3.6% in the elective-surgery group and the therapeutic-surgery group, respectively.
Conclusions: Among patients with early-stage oral squamous-cell cancer, elective neck dissection resulted in higher rates of overall and disease-free survival than did therapeutic neck dissection. (Funded by the Tata Memorial Centre; ClinicalTrials.gov number, NCT00193765.).
Source: PubMed